BioCryst Pharmaceuticals
BCRX
103 hedge funds and large institutions have $677M invested in BioCryst Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 17 closing their positions.
153% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 15
152% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $4.71M
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
47% more capital invested
Capital invested by funds: $461M → $677M (+$216M)
17% more funds holding
Funds holding: 88 → 103 (+15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$48.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$16.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.9M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$8.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.7M |
| 2 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$12.3M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.2M |
| 4 |
DM
Deerfield Management
New York
|
-$9.61M |
| 5 |
Millennium Management
New York
|
-$4.29M |
BCRX Hedge Fund Activity: Q2 2014 in Review
103 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2014, worth a combined $677M — up 47% from $461M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new BCRX positions and 17 closed out — a net gain of 16 holders — while 38 added to existing stakes and 15 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $48.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.7M sold.
- 103 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2014, up from 88 in Q1 2014.
- Funds reported $677M of BioCryst Pharmaceuticals stock for Q2 2014, up 47% quarter-over-quarter.
- 33 funds opened new BioCryst Pharmaceuticals positions in Q2 2014 and 17 closed out, a net change of +16 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2014 was Baker Bros. Advisors, an estimated $48.9M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $16.7M sold.
Based on aggregated 13F filings for Q2 2014.